Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer

Japanese Journal of Clinical Oncology

Volumn 32, Issue 7, 2002, Pages 238-243

  Terashita, Yukio ^a   Sasaki, Hidefumi ^a   Haruki, Nobuhiro ^a   Nishiwaki, Tadashi ^a   Ishiguro, Hideyuki ^a   Shibata, Yasuyuki ^a   Kudo, Junzo ^a   Konishi, Shigeru ^a   Kato, Joji ^a   Koyama, Hiroshi ^a   Kimura, Masahiro ^a   Sato, Atsushi ^a   Shinoda, Noriyuki ^a   Kuwabara, Yoshiyuki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Esophageal cancer; Immunohistochemistry; LightCycler; PPAR ; Prognosis

Indexed keywords

MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR MARKER; CELL RECEPTOR; TRANSCRIPTION FACTOR;

ANALYZER; ARTICLE; CANCER CELL; CANCER PATIENT; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE SEVERITY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM; ESOPHAGUS; ESOPHAGUS TUMOR; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 0036652257     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyf056     Document Type: Article

References (28)

1. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996;12:335-63.
2. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-70.
3. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med 1998;4:1046-52.
4. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR γ in gastric cancer and inhibitory effects of PPARγ agonist. Br J Cancer 2000;83:1394-400.
5. Lambel KG, Tugwood JD. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, inducing thiazolidinedione drugs. Eur J Biochem 1996;239:1-7.
6. Spiegelman BM. PPARγ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
7. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM. PPARγ promoters monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
8. Chang T, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000;60:1129-38.
9. Takeshima T, Fujiwara Y, Higuchi K, Arakawa T, Yano Y, Hasuma T, et al. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction ornithine, decarboxylase activity. Int J Oncol 2001;19:465-71.
10. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction apoptosis. Biochem Biophys Res Commun 2000;270:400-5.
11. Kubota T, Koshizuka K, Asou H, Williamson EA, Said JW, Holded S, et al. Ligand for peroxisome prolirator receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
12. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75-80.
13. Brockman JA, Gupta RA, DuBois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cell. Gastroenterology 1998;115:1049-55.
14. Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G, et al. PPAR gamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 2000;17:1157-64.
15. Kip1 in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
16. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7.
17. Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellar carcinoma. Br J Cancer 2001; 84:1640-7.
18. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999;1:330-9.
19. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: A microplume multisample fluorimeter with rapid temperature control. Biotechniques 1997;22:176-81.
20. Japanese Society for Esophageal Disease. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th ed. Tokyo: Kanehara 1999.
21. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998;19:49-53.
22. Sasaki H, Tanahashi M, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, et al. Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 2002;36:71-6.
23. Han SW, Greene ME, Pitts J, Wada RK, Sidell N. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARγ) in human neuroblastoma. Clin Cancer Res 2001;7:98-104.
24. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, et al. Involvement of p21(WAF1/Cip1), p27(Kip1) and p18(INK4c) in troglitazone-induced cell cycle arrest in human hepatoma cell lines. Hepatology 2001;33:1087-97.
25. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.
26. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks RN, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1996;96:3951-6.
27. Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) cyclin D1 expression in esophageal cancer. Oncology 1999;57: 311-7.
28. Japanese Society for Esophageal Disease. Prognostic significance of cyclin D1 and E-cadherin in patients with esophageal squamous cell carcinoma: Multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Disease. J Am Coll Surg 2001;192:708-18.